Topamax
Topiramate
Manufacturer: Johnson & Johnson Pharmaceutical R & D, LLC
FDA-Approved Indications (3)
As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome.
initial monotherapy for the treatment of partial-onset seizures in patients 2 years of age and older
Population: pediatric ≥2 years
initial monotherapy for the treatment of primary generalized tonic-clonic seizures in patients 2 years of age and older
Population: pediatric ≥2 years
Indications & Usage
1 INDICATIONS AND USAGE TOPAMAX is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy TOPAMAX is indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epilepsy TOPAMAX is indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. 1.3 Migraine TOPAMAX is indicated for the preventive treatment of migraine in patients 12 years of age and older.
💙 Support Programs
View all →Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.